List of Excipients in Branded Drug PHENTERMINE AND TOPIRAMATE EXTENDED-RELEASE

Generic Drugs Containing PHENTERMINE AND TOPIRAMATE EXTENDED-RELEASE

Company	Ingredient	NDC	Excipient
DrReddys Laboratories Inc	phentermine and topiramate extended-release	43598-624	CELLULOSE, MICROCRYSTALLINE
DrReddys Laboratories Inc	phentermine and topiramate extended-release	43598-624	ETHYLCELLULOSE
DrReddys Laboratories Inc	phentermine and topiramate extended-release	43598-624	GELATIN
DrReddys Laboratories Inc	phentermine and topiramate extended-release	43598-624	HYDROXYPROPYL CELLULOSE
DrReddys Laboratories Inc	phentermine and topiramate extended-release	43598-624	HYPROMELLOSE 2208
DrReddys Laboratories Inc	phentermine and topiramate extended-release	43598-624	TALC

What are the Most Frequently-Used Excipients in PHENTERMINE AND TOPIRAMATE EXTENDED-RELEASE?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	ETHYLCELLULOSE
1	GELATIN
1	HYDROXYPROPYL CELLULOSE
1	HYPROMELLOSE 2208
1	TALC

Phentermine and Topiramate Extended-Release: Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: August 23, 2026

Phentermine/topiramate extended-release is a small-molecule, oral combination product marketed in the United States as Qsymia. Its commercial value is linked to multiparticulate modified release, dose-specific capsule design, controlled exposure to phentermine and topiramate, and the regulatory complexity of reproducing a combination product with two active ingredients. The strongest excipient opportunities are in extended-release coating systems, capsule-in-capsule or multiparticulate technologies, taste and moisture control, and formulation support for generic or international products.

What is phentermine/topiramate extended-release?

Phentermine/topiramate extended-release combines a sympathomimetic anorectic, phentermine hydrochloride, with topiramate, an anticonvulsant that affects appetite and satiety pathways. Qsymia is approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults and certain adolescents with obesity or overweight plus a weight-related condition.[1]

The approved U.S. strengths are:

Strength	Phentermine HCl	Topiramate	Dosage form
Initial	3.75 mg	23 mg	Extended-release capsule
Recommended	7.5 mg	46 mg	Extended-release capsule
Titration	11.25 mg	69 mg	Extended-release capsule
Maximum	15 mg	92 mg	Extended-release capsule

Qsymia is taken once daily in the morning. The product uses extended-release topiramate and immediate-release phentermine exposure designed to support once-daily dosing while limiting peak-related tolerability problems.[1]

What excipients are used in Qsymia extended-release capsules?

The publicly disclosed formulation uses a multiparticulate approach with conventional pharmaceutical excipients. The FDA prescribing information identifies inactive ingredients including microcrystalline cellulose, sugar spheres, povidone, hypromellose, ethylcellulose, talc, gelatin, titanium dioxide and color additives.[1]

Functional role of the principal excipients

Excipient or material	Likely formulation role	Commercial relevance
Microcrystalline cellulose	Filler, pellet substrate or processing aid	Supports multiparticulate manufacture and capsule fill uniformity
Sugar spheres	Inert starter cores for drug-layered pellets	Enables reproducible coating and particle-size control
Povidone	Binder and drug-layering aid	Improves adhesion of active ingredients to starter cores
Hypromellose	Film former and release-control polymer	Can support drug layering, protective coating or release modulation
Ethylcellulose	Water-insoluble release-control polymer	Central candidate for sustained-release coating systems
Talc	Anti-tacking and coating-process aid	Reduces agglomeration during fluid-bed coating
Gelatin	Hard capsule shell	Supports conventional oral capsule manufacture
Titanium dioxide and colorants	Opacity and product identification	Important for strength differentiation and brand presentation

The label does not establish that each excipient performs a single, isolated function. In a multiparticulate system, coating weight, polymer grade, pore structure, particle size and process conditions often determine release performance more than the nominal identity of one excipient.

What formulation architecture protects the commercial profile?

The main technical challenge is not simply combining phentermine and topiramate in one capsule. It is maintaining independent control of the two active ingredients while delivering a consistent once-daily pharmacokinetic profile.

A commercial formulation is likely to include:

1. Separate drug-loaded multiparticulates for phentermine and topiramate.
2. Drug layering onto inert cores.
3. Polymer coatings that control topiramate release.
4. Immediate-release or minimally delayed phentermine delivery.
5. Encapsulation of the multiparticulate blend.
6. Tight control of pellet size, coating thickness and capsule fill weight.

This architecture creates several development barriers:

• Different active ingredients may require different granulation and coating conditions.
• Topiramate is used at a substantially higher mass than phentermine.
• Dose proportionality must be preserved across four strengths.
• Small changes in coating weight can change dissolution and exposure.
• The finished product must maintain blend uniformity despite different pellet populations.
• Capsule appearance and color must distinguish strengths and reduce medication errors.

A generic developer may therefore need a formulation that is pharmaceutically equivalent and bioequivalent without copying the branded excipient selection or manufacturing sequence.

What excipient strategies offer the strongest commercial opportunities?

1. Ethylcellulose-based controlled-release coatings

Ethylcellulose remains a practical platform for sustained-release multiparticulates. Suppliers can compete through aqueous dispersions, optimized particle-size distributions, lower process temperatures and improved coating uniformity.

Commercial opportunities include:

• Lower coating weight at equivalent release control.
• Reduced pellet agglomeration.
• Faster drying cycles.
• Improved robustness across different active loads.
• Consistent dissolution after storage.
• Compatibility with high-throughput fluid-bed coating.

A supplier that can demonstrate equivalent performance with reduced process time or lower solvent and energy use has a direct value proposition for generic manufacturers.

2. Hypromellose and ethylcellulose polymer systems

A mixed-polymer system can provide better control than a single polymer. Hypromellose can improve film formation and hydration, while ethylcellulose provides the principal insoluble barrier.

Potential advantages include:

• More predictable release across pH conditions.
• Better mechanical resistance during capsule filling.
• Reduced sensitivity to coating defects.
• Greater flexibility in tuning phentermine and topiramate exposure.
• A design-around path where branded patent claims cover a narrower polymer combination.

The strongest opportunity is a validated platform rather than a raw excipient sale. Generic companies may value prequalified coating systems, development protocols and dissolution libraries more than individual excipients.

3. Functionalized starter cores

Sugar spheres are established substrates, but alternative cores may reduce variability or improve manufacturing economics. Potential platforms include microcrystalline cellulose spheres, starch-based pellets and other inert multiparticulate cores.

Value drivers include:

• Narrower particle-size distribution.
• Higher mechanical strength.
• Lower friability.
• Better drug-loading capacity.
• Reduced dust generation.
• Improved compatibility with automated coating equipment.

Any alternative must preserve capsule fill uniformity and dissolution performance. A lower-cost core that creates unacceptable pellet variability has limited commercial value.

4. Taste masking and sprinkle-compatible formats

Qsymia is swallowed as a capsule, but alternative products may target patients who have difficulty swallowing. A sprinkle formulation, orally disintegrating product or smaller multiparticulate presentation could expand use in selected populations.

The technical issue is taste. Topiramate can produce an unpleasant oral sensory profile, while phentermine has its own bitterness. Commercial solutions may include:

• Polymer taste-masking layers.
• Lipid barriers.
• Ion-exchange resin complexes.
• Smaller coated pellets.
• Unit-dose sachets with controlled reconstitution.

Taste-masking layers must not materially delay or alter the intended release profile. This opportunity is more likely to support lifecycle management than a first generic entry.

5. Moisture-control excipient systems

Multiparticulate release coatings can be affected by humidity, plasticization and storage conditions. Moisture sorption may change polymer permeability and dissolution.

Commercial opportunities include:

• Low-moisture capsule formulations.
• Desiccant-enabled packaging.
• Moisture-barrier blister systems.
• Improved seal coatings.
• Excipient combinations with lower water activity.
• Stability-indicating dissolution specifications.

Packaging and excipient strategy should be developed together. A robust coating can still fail commercial stability if the capsule shell and packaging system permit moisture ingress.

What patents protect phentermine/topiramate extended-release?

Protection for Qsymia has historically involved several layers:

Protection category	Subject matter	Relevance to competitors
Combination composition	Phentermine and topiramate used together	May affect the product concept and strength combinations
Extended-release formulation	Controlled delivery of one or both active ingredients	Directly relevant to multiparticulate and polymer design
Method of treatment	Weight management using specified dose regimens	Can affect labeling and ANDA carve-outs
Titration and dosing	Dose escalation, maintenance and discontinuation protocols	Relevant to method-of-use exposure
Manufacturing process	Drug layering, coating, blending or encapsulation	Relevant to process design and trade-secret risk
Product presentation	Capsule strengths, packaging and risk-management requirements	Relevant to launch and regulatory operations

The FDA Orange Book is the controlling public source for listed patents and exclusivity information associated with an approved drug product.[2] Patent scope and remaining term should be assessed claim by claim. A formulation patent may cover a specific release profile or polymer system rather than every phentermine/topiramate ER capsule.

A generic sponsor must separate four questions:

1. Does the ANDA product infringe a listed patent?
2. Can the sponsor certify that the patent is invalid or not infringed?
3. Can the sponsor omit a patented method of use through a section viii statement?
4. Does the proposed product reproduce protected release characteristics even if it uses different excipients?

Patentability is strongest where the formulation combines a defined pharmacokinetic profile with specific particle architecture, coating composition or dissolution limits. Patent strength is weaker where claims rely on broad ingredient lists without meaningful structural or performance limitations.

When does phentermine/topiramate lose exclusivity?

FDA exclusivity and patent exclusivity are separate. Regulatory exclusivity depends on the approval pathway and pediatric or other statutory rights. Patent expiry depends on the specific patent, term adjustment, terminal disclaimers and any litigation outcome.

Qsymia is a small-molecule product. It does not have biosimilar exclusivity, and a biosimilar pathway is not relevant. Competition would proceed through an ANDA or, for a materially different product, potentially a 505(b)(2) application.[3]

A generic launch may occur through several routes:

Launch route	Typical legal position
Paragraph III certification	Launch after the relevant patent expires
Paragraph IV certification	Potential launch after notice, litigation resolution or statutory timing
Section viii carve-out	Market only non-patented indications or dosing instructions
505(b)(2)	Develop a different formulation, route, strength or clinical profile

The commercial launch date depends on the latest enforceable patent and any settlement restrictions. It cannot be inferred solely from the original Qsymia approval date.

What is the Orange Book status of Qsymia?

The Orange Book identifies approved strengths, dosage forms, reference-listed-drug information, listed patents and exclusivity data.[2] Qsymia should be reviewed by:

• Product number.
• Strength.
• Capsule dosage form.
• Patent listing.
• Patent expiration.
• Pediatric exclusivity.
• Reference product status.
• Any delisting or administrative change.

The strategic point is that the four strengths do not automatically create four independent patent barriers. A single formulation or composition patent may cover multiple strengths, while a method-of-use patent may apply only to selected dosing or patient populations.

Which companies are challenging phentermine/topiramate ER?

Potential challengers are generic pharmaceutical companies with capabilities in:

• Multiparticulate coating.
• Controlled-release oral solids.
• Combination-product ANDA development.
• In vitro-in vivo correlation.
• High-sensitivity dissolution testing.
• Controlled-substance handling for phentermine.

Public challenge activity should be tracked through FDA approval records, Paragraph IV notices, district court dockets and patent settlements. The absence of a visible public challenge does not establish that no generic development is underway. Generic sponsors may remain confidential until an ANDA filing or litigation event becomes public.

The most credible challengers are likely to be companies that already manufacture extended-release pellets or controlled-release capsules. A conventional tablet manufacturer would face greater development risk because the reference product's multiparticulate performance may be difficult to reproduce with a simple matrix tablet.

What patent litigation and settlement issues affect generic launch?

Litigation risk centers on:

• Whether the reference product's listed patents are valid.
• Whether alternative polymer systems avoid infringement.
• Whether a generic's release profile falls within claim limitations.
• Whether a Paragraph IV notice triggers a 30-month stay.
• Whether settlement terms restrict launch before patent expiry.
• Whether an authorized generic or license is included in the agreement.

Settlements can create commercial entry dates that differ from the nominal patent expiry. A transaction involving an excipient supplier should therefore evaluate both legal freedom to operate and the expected timing of generic market formation.

How strong is the excipient and formulation patent estate?

The formulation estate is strongest when it contains multiple claim layers:

1. Composition claims covering the active combination.
2. Structural claims covering pellets, coatings or capsule architecture.
3. Performance claims covering dissolution or exposure.
4. Process claims covering drug layering and coating.
5. Use claims covering obesity treatment and titration.

For excipient companies, the principal risk is that a formulation patent may be broad enough to capture a substitute polymer system even when the supplier does not use the branded excipients. The principal opportunity is a design-around formulation with a distinct particle structure, coating chemistry or release mechanism.

A robust development package should include:

• Comparative dissolution across pH conditions.
• Accelerated and long-term stability.
• Particle-size and coating-thickness data.
• Capsule fill uniformity.
• Dose proportionality.
• Pharmacokinetic comparison.
• Extractables and leachables assessment.
• Freedom-to-operate review for polymer and process claims.

How does Qsymia compare with competing obesity drugs?

Product class	Example	Primary formulation opportunity	Generic or biosimilar pathway
Phentermine/topiramate ER	Qsymia	Multiparticulate ER capsule and combination-product design	ANDA
Orlistat	Xenical, Alli	Lipid digestion inhibition and capsule formulation	ANDA
Naltrexone/bupropion ER	Contrave	Dual-active extended-release tablet	ANDA
Liraglutide	Saxenda	Injectable peptide stability and device delivery	Biosimilar or follow-on biologic framework
Semaglutide	Wegovy, Ozempic	Peptide formulation, injection and device systems	Biosimilar or follow-on biologic framework
Tirzepatide	Zepbound, Mounjaro	Peptide stabilization and injection delivery	Biosimilar or follow-on biologic framework

Phentermine/topiramate has a lower manufacturing barrier than injectable incretin therapies but a higher formulation barrier than a conventional immediate-release capsule. The opportunity is therefore attractive for excipient suppliers with oral modified-release expertise, not merely commodity capsule or filler manufacturers.

What revenue exposure and commercial opportunities exist?

Qsymia revenue is exposed to generic entry, competing obesity therapies and payer coverage. The product's commercial durability depends on its low-dose oral format, established clinical data and potential cost advantage relative to injectable therapies.

The main commercial opportunities are:

• Polymer systems for generic ER capsules.
• Coating process technology.
• Alternative starter cores.
• Moisture-resistant packaging.
• Taste-masked sprinkle products.
• Pediatric or swallowing-impaired patient presentations.
• International combination products.
• Contract development and manufacturing for ANDA sponsors.
• Excipient supply agreements tied to formulation scale-up.
• Licensed design-around formulations.

The most investable opportunity is usually a qualified multiparticulate platform that can be applied to several controlled-release products. A single-product excipient sale has lower strategic value than a platform supported by formulation data, regulatory documentation and manufacturing scale.

What generic launch scenarios exist?

Three scenarios are commercially relevant:

Early Paragraph IV entry

A challenger asserts that listed patents are invalid or not infringed. The sponsor may launch after litigation or settlement, subject to first-filer rights and other statutory constraints.

Patent-expiry entry

Multiple generic products launch after the last enforceable patent expires. Price erosion may be rapid because phentermine and topiramate are established small molecules with relatively low active-ingredient cost.

Differentiated 505(b)(2) entry

A sponsor develops a new sprinkle, orally disintegrating or alternative-release product. This can support lifecycle differentiation but may require additional clinical or pharmacokinetic studies and may face separate patent claims.

How does geographic coverage affect opportunity?

The U.S. market is governed by FDA approval, Orange Book listings and Hatch-Waxman litigation. Other markets apply different rules:

• European products may require national or centralized regulatory review and separate patent analysis.
• Canada and Australia have distinct linkage and patent-notification systems.
• Emerging markets may have weaker enforcement but greater price sensitivity.
• Local manufacturing requirements can favor regional excipient and contract manufacturing partners.
• Colorants, gelatin sources and pharmaceutical-grade polymer specifications may vary by jurisdiction.

A global excipient strategy should avoid reliance on a single colorant, animal-derived capsule material or region-specific supplier qualification.

Key Takeaways

• Phentermine/topiramate ER is a multiparticulate, once-daily oral combination product with four marketed strengths.
• The core formulation opportunity is controlled-release coating of separate drug-loaded particles, followed by capsule filling.
• Ethylcellulose, hypromellose, povidone, microcrystalline cellulose and starter cores are commercially important formulation components.
• Generic competition will require more than active-ingredient equivalence. Dissolution, exposure, pellet structure and dose uniformity are central development issues.
• The product is subject to small-molecule ANDA competition, not biosimilar competition.
• Excipient suppliers with coating technology, moisture control and formulation support have stronger opportunities than commodity excipient vendors.
• Patent risk should be assessed across composition, formulation, process, method-of-use and performance claims.
• Orange Book records, Paragraph IV activity, litigation and settlement terms determine practical launch timing.
• The most valuable commercial asset is a scalable, design-around multiparticulate platform supported by regulatory and manufacturing data.

FAQs

Can phentermine/topiramate ER be formulated as a tablet instead of a capsule?

Yes, but a tablet must reproduce the required release and exposure profile. A matrix tablet may face greater development risk than a multiparticulate capsule if the reference product relies on independently coated particle populations.

Are the excipients in Qsymia individually patent protected?

Most listed excipients are well-established pharmaceutical materials. Patent risk generally arises from their combination, coating architecture, process conditions or defined release performance rather than from the excipient identity alone.

Is an authorized generic version of Qsymia commercially important?

Yes. An authorized generic could moderate price erosion, control supply and influence the timing and economics of independent generic entry. Its existence depends on commercial and settlement arrangements.

Could a sprinkle formulation create a new market position?

Yes. A sprinkle or taste-masked multiparticulate product could address swallowing limitations and support lifecycle management, provided the new presentation preserves dose accuracy and the approved pharmacokinetic profile.

Which excipient supplier capabilities matter most for this product?

The highest-value capabilities are fluid-bed coating, polymer-film engineering, pellet-size control, dissolution method development, moisture management and scale-up from laboratory batches to commercial manufacture.

References

1. U.S. Food and Drug Administration. (2024). Qsymia (phentermine and topiramate extended-release) capsules: Prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
3. U.S. Food and Drug Administration. (2024). ANDA, 505(b)(2), and 505(b)(1) regulatory pathways: Small-molecule drug products.